Royalty Pharma Reports Second Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Royalty Pharma plc (RPRX) Tops Q2 Revenue Estimate
August 4, 2022 8:00 AM EDTRoyalty Pharma plc (NASDAQ: RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
... More